JPWO2022217231A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022217231A5 JPWO2022217231A5 JP2023561628A JP2023561628A JPWO2022217231A5 JP WO2022217231 A5 JPWO2022217231 A5 JP WO2022217231A5 JP 2023561628 A JP2023561628 A JP 2023561628A JP 2023561628 A JP2023561628 A JP 2023561628A JP WO2022217231 A5 JPWO2022217231 A5 JP WO2022217231A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- present
- combination
- concentration
- buffers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171429P | 2021-04-06 | 2021-04-06 | |
| US63/171,429 | 2021-04-06 | ||
| PCT/US2022/071562 WO2022217231A1 (en) | 2021-04-06 | 2022-04-05 | Formulations of l-asparaginase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515555A JP2024515555A (ja) | 2024-04-10 |
| JPWO2022217231A5 true JPWO2022217231A5 (https=) | 2025-04-14 |
| JP2024515555A5 JP2024515555A5 (https=) | 2025-04-14 |
Family
ID=81748398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561628A Pending JP2024515555A (ja) | 2021-04-06 | 2022-04-05 | Ｌ－アスパラギナーゼの製剤 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4319818A1 (https=) |
| JP (1) | JP2024515555A (https=) |
| KR (1) | KR20230165799A (https=) |
| CN (1) | CN117377494A (https=) |
| AR (1) | AR125301A1 (https=) |
| AU (1) | AU2022256071A1 (https=) |
| BR (1) | BR112023019862A2 (https=) |
| CA (1) | CA3213726A1 (https=) |
| CL (1) | CL2023002983A1 (https=) |
| CO (1) | CO2023014093A2 (https=) |
| MX (1) | MX2023011693A (https=) |
| WO (1) | WO2022217231A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022211829A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7985548B2 (en) | 2006-03-03 | 2011-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| KR102783452B1 (ko) * | 2016-06-01 | 2025-03-19 | 세르비에 아이피 유케이 리미티드 | 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법 |
| JP2021505661A (ja) * | 2017-11-30 | 2021-02-18 | ジャズ ファーマシューティカルズ アイルランド リミテッド | アスパラギナーゼを用いた治療法 |
| JP2022553399A (ja) * | 2019-10-25 | 2022-12-22 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 組換えｌ－アスパラギナーゼ |
-
2022
- 2022-04-05 CN CN202280032191.2A patent/CN117377494A/zh active Pending
- 2022-04-05 KR KR1020237037007A patent/KR20230165799A/ko active Pending
- 2022-04-05 JP JP2023561628A patent/JP2024515555A/ja active Pending
- 2022-04-05 AU AU2022256071A patent/AU2022256071A1/en active Pending
- 2022-04-05 BR BR112023019862A patent/BR112023019862A2/pt unknown
- 2022-04-05 AR ARP220100846A patent/AR125301A1/es unknown
- 2022-04-05 MX MX2023011693A patent/MX2023011693A/es unknown
- 2022-04-05 WO PCT/US2022/071562 patent/WO2022217231A1/en not_active Ceased
- 2022-04-05 EP EP22724215.3A patent/EP4319818A1/en active Pending
- 2022-04-05 CA CA3213726A patent/CA3213726A1/en active Pending
-
2023
- 2023-10-05 CL CL2023002983A patent/CL2023002983A1/es unknown
- 2023-10-23 CO CONC2023/0014093A patent/CO2023014093A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| JP2002544174A5 (https=) | ||
| FI4267105T3 (fi) | Vasta-ainekoostumuksia ja niiden käyttömenetelmiä | |
| TWI633887B (zh) | 用於預防及／或治療多囊性腎臟病之藥物 | |
| JP2010511665A5 (https=) | ||
| JP2003522735A (ja) | Ｉｌ−１１に関する組成物 | |
| RU2007119724A (ru) | Композиции, содержащие эктинэсайдин и дисахарид | |
| JP2013511522A (ja) | ダプトマイシン製剤 | |
| NL9001714A (nl) | Farmaceutisch prepraat voor orale toediening bevattende nac. | |
| JP2636499B2 (ja) | プラスミノーゲン活性化因子蛋白の薬学的組成物 | |
| US8119595B2 (en) | Stable, aqueous solution of human erythropoietin, not containing serum albumin | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| JP2021527084A5 (https=) | ||
| ES2296529B1 (es) | Composicion farmaceutica con promotores de absorcion. | |
| JPWO2022217231A5 (https=) | ||
| JPWO2022146947A5 (https=) | ||
| RU2690677C1 (ru) | Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью | |
| JPWO2020264333A5 (https=) | ||
| EP3493832A1 (en) | Pharmaceutical formulations of c1 esterase inhibitor | |
| CN119838019A (zh) | 包含溶栓肽-四氢异喹啉缀合物的药物组合物 | |
| EP1488800A1 (en) | Agent for the treatment of protozoal diseases | |
| CN119950703B (zh) | 抗体制剂 | |
| WO2022161554A4 (es) | Composición farmacéutica que comprende el ghrp-6 | |
| US10682326B1 (en) | Stable melphalan liquid injectable formulations | |
| JPWO2019239386A5 (https=) |